How we work with Pharma
The pharmaceuticals landscape is changing, in a positive way, and there is a growing appetite from both business and regulators for new technology and processes that can bring cost and sustainability savings.
Read on or watch our video with our Non-Exec Director, Joe de Sousa (20+ years in pharma) and our CEO, Holly Reeve
The challenge
A key challenge for the pharmaceuticals sector is cost and the economics of chemical processes. The raw materials used in pharmaceutical production can be expensive and difficult to source but in addition to this, many chemical reactions used in drug synthesis require large amounts of energy for heating, cooling or pressure which contributes to operational expenses. They also generate significant waste, including hazardous byproducts, that require costly disposal or treatment according to environmental regulations.
This capital-intensive structure is driving a transition to more efficient, sustainable, and cost-effective chemical processes to ensure the long-term profitability of the pharmaceuticals sector and secure accessibility of new drugs.
On top of costs, there is also the challenge of sustainability. Many pharmaceutical manufacturing processes remain dependent on 20th Century chemistry which has big implications on the environment, primarily due to its chemical-intensive nature, resource consumption and waste generation.
With growing pressure on pharmaceutical companies to adopt more sustainable and environmentally friendly chemical processes, the industry is ready to invest in the technology and processes that can deliver on sustainability, if it makes commercial sense.
On top of costs, there is also the challenge of sustainability. Many pharmaceutical manufacturing processes remain dependent on 20th Century chemistry which has big implications on the environment, primarily due to its chemical-intensive nature, resource consumption and waste generation.
With growing pressure on pharmaceutical companies to adopt more sustainable and environmentally friendly chemical processes, the industry is ready to invest in the technology and processes that can deliver on sustainability, if it makes commercial sense.
Delivering real impact
HydRegen is bringing 21st Century chemistry to the pharmaceuticals industry with solutions to chemical transformations that will have a real impact whilst also delivering on costs. By providing the option to move away from precious metals or heavy metal catalysts in chemical processes, we are delivering cleaner, safer and more sustainable chemical manufacture whilst also removing supply chain complexities and improving waste stream management.
HydRegen’s technologies are a bio-based alternative to precious metals in chemical manufacturing allowing pharmaceutical companies to run cleaner processes and less energy intensive reactions. However, we are not like other biotech companies as our catalysts are broad scope.
We work with the pharmaceuticals sector in a few different ways. Firstly, we sell our broad scope catalyst products into medicinal chemistry where they can do discovery chemistry. In discovery chemistry the interest is in clean processes and clean chemical transformations that give specificity.
Secondly, we are also working on developing processes that meet commercial manufacturing needs. In process development and manufacturing processes the focus is around specificity and operability. HydRegen can take a customer’s molecule of interest and demonstrate that it is compatible with our catalysts which are both robust and have a range of attractive operating parameters.
HydRegen has already demonstrated with a number of meaningful examples of relevant target molecules that its technology can make a real difference to Active Pharmaceutical Ingredients (APIs) that are currently being used across the world in all sorts of different therapy areas. See our process booklet for more details.
Collaboration
Biotech and pharmaceutical collaborations are increasingly essential in modern drug development to accelerate scientific breakthroughs, improve patient outcomes and bring new treatments to market more efficiently. In an era of rapid scientific advancement, such collaborations are essential to addressing complex health challenges.
HydRegen’s ability to combine its innovative solutions with the resources, scale and expertise of the pharmaceuticals industry will help drive more efficient and economical drug discovery and development whilst reducing the capital and environmental impacts.
If you’d like to find out more, get in touch: products@hydregenoxford.com